Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 1215-1220

  Varier, Radhika A ^a   Swaminathan, V ^a   Balasubramanyam, Karanam ^a   Kundu, Tapas K ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

AIB1; amplified in breast cancer 1; CBP; CREB binding protein; CTPB; HAT; HDAC; histone acetyltransferase; histone deacetylase; N (4 chloro 3 trifluoromethyl phenyl) 2 ethoxy 6 pentadecyl benzimidine; p300; p300 CBP associated factor; PCAF

Indexed keywords

ACETYL COENZYME A; ANACARDIC ACID; BENZIMIDAZOLE DERIVATIVE; HISTONE; HISTONE ACETYLTRANSFERASE; N (4 CHLORO 3 TRIFLUOROMETHYLPHENYL) 2 ETHOXY 6 PENTADECYLBENZIMIDINE; UNCLASSIFIED DRUG;

ACETYLATION; CANCER; CONFERENCE PAPER; COVALENT BOND; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE CONTROL; GENETIC TRANSCRIPTION; MOLECULE; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN FUNCTION;

ACETYLATION; ACETYLTRANSFERASES; ANIMALS; CHROMATIN; ENZYME INHIBITORS; FORECASTING; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS;

EID: 4143089466     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.05.038     Document Type: Conference Paper

References (37)

1. Van Holde KE. Chromatin 1988. NewYork: Springer-Verlag.
2. Wolfe A. Chromatin: structure and function, 3rd ed. Academic Press; 1998.
3. Turner BM. Chromatin and gene regulation molecular mechanisms in epigenetics. Blackwell Science; 2001.
4. Van Holde K.E., Yager T. Models for chromatin remodeling: a critical comparison. Biochem. Cell Biol. 81:2003;169-172
5. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 70:2001;81-120
6. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. MolBio. Rev. 64:2000;435-459
7. Struhl K. Histone deacetylase activity of Rpd3 is important for transcriptional repression in vivo. Genes Dev. 12:1998;599-606
8. Kuo M.H., Allis C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays. 20:1998;615-626
9. Fry C.J., Peterson C.L. Transcription. Unlocking the gates to gene expression. Science. 295:2002;1847-1848
10. Muraoka M., Konishi M., Kikuchi-Yanoshita R., et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene. 12:1996;1565-1569
11. Phillips A.C., Vousden K.H. Acetyltransferases and tumour suppression. Breast Cancer Res. 2:2000;244-246
12. Xu J., Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol. Endocrinol. 17:2003;1681-1692
13. Champagne N., Pelletier N., Yang X.J. The monocytic leukemia zinc finger protein MOZ is a Histone Acetyltransferase. Oncogene. 20:2001;404-409
14. Milne T.A., Briggs S.D., Brock H.W., et al. MLL Targets SET Domain Methyltransferase Activity to Hox Gene Promoters. Mol. Cell. 10:2002;1107-1117
15. Nakamura T., Mori T., Tada S., et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell. 10:2002;1119-1128
16. Panagopoulos I., Fioretos T., Isaksson M., et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(1016)(q22p13). Hum. Mol. Genet. 10:2001;395-404
17. Liang J., Prouty L., Williams B.J., et al. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood. 92:1998;2118-2122
18. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 387:1997;733-736
19. Puri P.L., Sartorelli V., Yang X.J., et al. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol. Cell. 1:1997;35-45
20. Blobel G.A., Nakajima T., Eckner R., et al. CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc. Natl. Acad. Sci. USA. 95:1998;2061-2066
21. Rebel V.I., Kung A.L., Tanner E.A., et al. Distinct roles for CREB-binding protein and p300 in ematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. USA. 99:2002;14789-14794
22. Murata T., Kurokawa R., Krones A., et al. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum. Mol. Genet. 10:2001;1071-1076
23. Kalkhoven E., Roelfsema J.H., Teunissen H., et al. Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome. Hum. Mol. Genet. 12:2003;441-450
24. Rouaux C., Jokic N., Mbebi Boutiller S., et al. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22:2003;6537-6549
25. Lusic M., Marcello A., Cereseto A., Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J. 22:2003;6550-6561
26. Quivy V., Adam E., Collette Y., et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J. Virol. 76:2002;11091-11103
27. Marks P., Rifkind R.A., Richon V.M., et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 1:2001;194-202
28. Richon V.M., Zhou X., Rifkind R.A., Marks P.A. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 27:2001;260-264
29. Cullis P.M., Wolfenden R., Cousens L.S., Alberts B.M. Inhibition of histone acetylation by N-[2-(S-coenzyme A) acetyl] spermidine amide, a multisubstrate analog. J. Biol. Chem. 257:1982;12165-12169
30. Lau O.D., Kundu T.K., Soccio R.E., et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell. 5:2000;589-595
31. Kundu T.K., Palhan V., Wang Z., et al. Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol. Cell. 6:2000;551-561
32. Polesskaya A., Naguibneva I., Fritsch L., et al. CBP/p300 and muscle differentiation: no HAT, no muscle. EMBO J. 20:2001;6816-6825
33. Balasubramanyam K., Swaminathan V., Ranganathan A., Kundu T.K. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278:2003;19134-19140
34. Thompson P.R., Kurooka H., Nakatani Y., Cole P.A. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J. Biol. Chem. 276:2001;33721-33729
35. Lau O.D., Courtney A.D., Vassilev A., et al. p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism. J. Biol. Chem. 275:2000;21953-21959
36. Poux A.N., Cebrat M., Kim C.M., Cole P.A., Marmorstein R. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc. Natl. Acad. Sci. USA. 99:2002;14065-14070
37. Balasubramanyam K, Altaf M, Varier RA, et al. Polyisoprenylated benzophenone, garcinol, a natural HAT inhibitor represses chromatin transcription and alters global gene expression. J Biol Chem 2004 (in press).